To determine the activity and safety of 177 Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk of early progression; and to identify potential prognostic and predictive biomarkers from imaging, blood, and tissue.
To evaluate the association between SpaceOAR and radiation dosing, toxicity and quality-of-life versus no spacer across all radiotherapy modalities for prostate cancer. A systematic search of the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase was performed from database inception through May 2020.
Radical cystectomy (RC) is the gold standard treatment for patients with muscle-invasive or refractory non-muscle invasive bladder cancer. It is estimated that approximately 64% and 13% of RC patients experience any complication and major complications, respectively.
To study the telomeras revers transcriptas (TERT) mutation and the p53 pathway in T1 urinary bladder cancer (UBC). This prospectively performed population-based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992-2001, inclusively.
-VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men – San Francisco, CA (UroToday.com) — Veracyte, Inc. announced new data from two studies that further demonstrate the Decipher® Prostate Genomic Classifier (GC) provides prognostic information that can help physicians tailor treatment decisions for men with prostate cancer. The findings will be presented at […]
Sam Chang: Hello, everyone. I have the great honor, actually, to introduce Dr. Jonathan Coleman from Memorial Sloan Kettering Cancer Center. He’s a full professor there. I’ve had the honor and pleasure to know Jonathan for many years. He kept me out of trouble when I was a fellow there at Sloan Kettering, now a couple […]
Non-muscle invasive bladder cancers (NMIBC) constitute the majority of bladder cancer diagnoses. NMIBCs are stratified based on the risk of progression to muscle-invasive disease into low, intermediate, and high-risk groups. NMIBC has the highest lifetime treatment costs of all cancers in the USA.
Our investigation in a large prospective cohort of 1057 biopsied men showed a significantly larger area under the ROC curve (AUC) for Prostate Health Index (PHI) density (PHID) in comparison with PHI alone. In this well-balanced group with 552 men with prostate cancer (PCa) and 505 without PCa from two tertiary centers in Germany the […]
~ Global Phase 3 Trial Will Establish Therapeutic Equivalence Between TAVT-45 Granules for Oral Suspension and Zytiga® Tablets in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC) and Metastatic Castrate Resistant Prostate Cancer (mCRPC) ~ ~ Potential to Become First FDA-Approved Granules for Oral Suspension Formulation of Abiraterone Acetate Which Reduces Pill Burden for Patients […]
Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) atlas, we performed single-cell RNA sequencing (scRNA-seq) of hematopoietic and non-hematopoietic subpopulations from tumor and tumor-adjacent tissue of treatment-naive ccRCC resections.
